Searched for
DRUGS PRICE
Japan's Takeda bets on dengue vax to reshape India playbookTakeda Pharmaceutical's new dengue vaccine Qdenga received approval in India. The vaccine is expected to launch commercially in early 2027....- The whey revolution: America's protein craze is changing dairy economicsWhey protein, once a cheesemaking byproduct, is now highly sought after by consumers. Social media trends and dietary advice are driving th...
- For GLP-1 users, the in-store clothes shopping trip is backMany consumers using weight-loss drugs are now shopping more in physical stores. Sizing changes prompt shoppers to try on clothes, increasi...
- Nayab Saini says BJP to form govt in Punjab, procure all crops at MSPHaryana Chief Minister Nayab Singh Saini stated the BJP will win Punjab polls next year. He assured farmers that all crops would be procure...
- Losing weight fast on GLP-1 drugs? Your hair could be the next thing to goDermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen efflu...
- Maharashtra FDA trains guns on overpriced drugsMaharashtra FDA plans to approach the NPPA regarding exorbitant drug prices. The agency is examining data and will take action against unet...
- Trump administration to end Medicare Part D subsidy after 2026The Trump administration will end a Medicare Part D subsidy program after 2026. Insurers have gained enough experience to price plans accur...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...
- US tariff proposal wake-up call for Indian pharma to diversify, innovate: ExpertsUS pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...
- Easy access, rising addiction: The new face of Northeast’s drug problemNortheast India’s narcotics crisis is no longer confined to cross-border trafficking. As heroin becomes widely available across parts of As...
- AstraZeneca 'magic' faces rare test after trial failure, share slideAstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted...
- Tariff hike by US will only increase drug prices: Dr Reddy's CEOUS tariff increases on generic medicines will lead to higher drug prices in India. Dr Reddy's Laboratories CEO Erez Israeli stated relocati...
- Tariffs alone will not produce sustainable generic medicine in US: IPAThe Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair...
- Generic drugmaker Sandoz to engage with US after Trump tariff threatUS President Donald Trump threatened steep tariffs on generic drugmakers. He stated medicines must be manufactured locally or face signific...
- Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investorsDonald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
Load More
